Adrenomed is a startup based in Germany, most recent round Series-c-plus, 1 tracked investor.
Based in Germany, Adrenomed is a startup founded in 2009. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
Adrenomed is a clinical-stage biopharmaceutical company based in Germany. It develops novel therapies, including its lead product Adrecizumab, for life-threatening conditions like septic shock.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.